Corporate Supporters

The ONS Corporate Council

The ONS Corporate Council is an exclusive, high-level opportunity available to a limited group of industry supporters. In the spirit of true partnership, it was created to reinforce your company’s industry leadership and recognize your essential role in advancing the oncology nursing profession. Learn more about our Corporate Council members.

Exclusive Benefits

  • High-level sponsor recognition at our national conferences, ongoing recognition and positioning in ONS communications, and year-round acknowledgement on the ONS website
  • ONS Corporate Council logo to help elevate your communication and promotional efforts
  • Key engagement opportunities with ONS executive leadership and ONS Board of Directors
  • Collaboration opportunities with other Corporate Council members and ONS
  • Priority updates and invitations to ONS sponsored events, ONS news, and ONS initiatives
  • Discounts and complimentary services

The investment for this fully integrated sponsorship opportunity is $140,000 per year.

Please contact busdev@ons.org for more information. 

ONS Corporate Council Members

Amgen Oncology

AstraZeneca Pharmaceuticals LP

Bristol Myers Squibb

Daiichi-Sankyo

Eisai Inc.

As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). Learn more about Eisai Inc. and our patient assistance program.

Genentech, Inc

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development

Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Merck

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates, with the potential to improve the treatment of advanced cancers.

Mylan

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Learn more about our patient assistance program.

Pfizer Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. Learn more about our patient assistance program.

Regeneron

 

Industry Relations Panel

Industry supporters may also join our new Industry Relations Panel, which offers two tiers of support at $50,000 and $25,000 per year. Please contact busdev@ons.org for more information. 

Industry Relations Panel members receive:

  • Recognition at our national conferences, ongoing recognition and positioning in ONS communications, and year-round recognition on the ONS website
  • Key engagement opportunities with ONS senior leadership
  • Collaboration opportunities with other Industry Relations Panel members and ONS
  • Discounts and complimentary services

Industry Relations Panel Members